Sequenom: A Reversal Of Misfortune
Marty Chilberg • 27 Comments
Marty Chilberg • 27 Comments
Sequenom 2013 Operating Results Review
Tue, Mar. 1, 5:35 PM
Fri, Feb. 26, 11:02 AM
- Results from a recent study show Biocept's (BIOC +2%) liquid biopsy test that detects bits of tumor-related DNA in the blood agreed with tissue biopsy results 93% of the time in 74 lung cancer patients. The data were presented in a poster session at the UCSD Moores Cancer Center Industry/Academia Translational Oncology Symposium in San Diego, CA.
- Biocept's test detects circulating tumor DNA (ctDNA) in a peripheral blood sample obtained via a routine blood draw. Tumors consistently shed bits of DNA that circulate in the blood which has potential for detecting and monitoring cancer. Because the amounts of ctDNA are very small, the clinical utility wasn't there until high powered sequencers became available, such as those made by Illumina (ILMN +1.4%). The value proposition of liquid biopsy is lower cost, greater convenience and much more patient-friendly that traditional tissue biopsy.
- Related tickers: (TROV -4.5%)(TBIO +6.6%)(SQNM -2.1%)(CDNA +2.8%)
Wed, Feb. 17, 7:08 AM
- Researchers at Cal State say they have developed a liquid biopsy test for the detection of prostate cancer that is based on a single drop of saliva. They claim that it can be performed in 10 minutes and is 100% accurate.
- Professor of oncology David Wong and prostate cancer surgeon and urologic oncologist Dr. David Samadi expect to start clinical trials by the end of this year. If successful, they say FDA clearance could happen within the next two years.
- A tumor sheds tiny amounts of DNA that the medical community has discovered circulate in the blood and can be found in other body fluids such as urine and, apparently, saliva. This cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) can be detected and analyzed using state-of-art sequencers such as those made by Illumina (NASDAQ:ILMN). This is called "liquid biopsy" because of the sample source. A traditional biopsy is performed on a tissue sample.
- Proponents of the liquid biopsy concept say it represents a paradigm shift in the detection and management of cancer since it has the potential for low-cost, non-invasive cancer screening and monitoring.
- Related tickers: (NASDAQ:TROV)(NASDAQ:TBIO)(NASDAQ:SQNM)(NASDAQ:BIOC)(NASDAQ:CDNA)
Wed, Feb. 10, 11:35 AM
- Illumina (ILMN +2.4%) taps board member and former Google executive Jeff Huber to lead Grail, its startup company that is developing a test to detect cancers at their earliest stages.
- Mr. Huber's 12-year Google career involved working on advertising products, Google Maps, Google Earth and the life sciences arm of Google X.
- Grail was started in January with more than $100M in funding from the likes of tech titans Bill Gates and Jeff Bezos. Its aim is to develop a "pan-cancer" screening test that can detect very minute levels of tumor-associated material in the blood called cell-free DNA. The process is called a liquid biopsy in light of its similar diagnostic objective to a tissue biopsy, that is, to detect very early-stage cancer. It will use Illumina's latest sequencing technology to analyze the samples. It expects to initiate a large clinical trial in 2017.
- Illumina invested $40M in Grail's first funding round and owns more than 50% of the company.
- Related tickers: (TROV -1.3%)(TBIO +5.4%)(SQNM +6.5%)(BIOC -0.7%)(CDNA -2.5%)
Thu, Jan. 7, 3:45 PM
- Struggling biotech Sequenom (SQNM -2.1%) announces its plan to cut costs and boost its growth prospects. The main points:
- The divestment of its Research Triangle Park, NC operations and the transfer of the work to its San Diego facility.
- The recruitment of strategic partners for the commercialization of its oncology liquid biopsy technology and a concomitant reduction in R&D spending.
- A 20% reduction in headcount (110 jobs).
- Management believes the moves will save over $20M in operating costs on an annualized basis by the end of the year.
- The company needs to do something. Shares have lost 70% of their value since mid-2015.
Dec. 11, 2015, 12:39 PM
- BioTime's (BTX -1.9%) board sets December 21 as the record date for the distribution of a portion of its stake in subsidiary OncoCyte to BioTime shareholders who will receive one share of OncoCyte common stock for every 20 BioTime common shares held. The distribution, expected to occur on December 31, will reduce BioTime's ownership position to ~58.6% from ~76.4%.
- OncoCyte is not publicly traded at present, but intends to apply for listing on the NYSE MKT under the symbol "OCX" in the coming weeks. In the event that the listing is not approved, it will arrange for the trading of its shares on the OTC Bulletin Board no later than December 31.
- OncoCyte develops "liquid biopsy" diagnostic tests that detect cancer biomarkers in blood or urine.
- Liquid biopsy-related tickers: (TROV -4.5%)(TBIO +3.6%)(SQNM -1.5%)(BIOC -4%)(CDNA -2%)
Nov. 4, 2015, 4:44 PM
- Sequenom (NASDAQ:SQNM): Q3 EPS of -$0.08 beats by $0.01.
- Revenue of $29.9M (-21.2% Y/Y) misses by $1.45M.
Nov. 3, 2015, 5:35 PM
- ACAS, ACLS, ACXM, AEL, AHT, ALB, ALR, ANDE, ARC, AREX, ARPI, ATO, AVG, AWAY, AWK, BGC, BKCC, BKD, BNFT, BOJA, BREW, BRKR, BWXT, CAA, CBPX, CCRN, CDI, CDXS, CF, CJES, CLR, CNAT, CODI, COHR, CPE, CSC, CSGS, CSII, CSLT, CTL, CVG, CVT, CXO, CXW, DCO, DOOR, DPM, DXCM, DYN, EGAN, ENVA, EOX, EPAM, EPM, EQC, ETE, ETP, EVAR, EVTC, EXAM, FB, FC, FEYE, FLT, FOE, FPRX, FRSH, FRT, FTD, FUEL, G, GDDY, GPOR, GTY, GUID, HABT, HASI, HDP, HIVE, HOLX, HR, HRTG, HUBS, IL, IO, JKHY, JONE, JRVR, KAI, KAR, KIM, KING, KND, KW, LADR, LCI, LDRH, LGCY, LHCG, LPSN, MATX, MB, MBI, MCHP, MCHX, MELI, MET, MHLD, MITT, MNTX, MOSY, MRIN, MRO, MTDR, MTRX, MUSA, MWA, MYRG, NLY, NNBR, NOG, NP, NWPX, OME, OSUR, PDLI, PE, PEIX, PFMT, PFSI, PGTI, PHH, PMT, POWR, PRA, PRI, PRU, PSEC, QCOM, QUOT, RDEN, RENT, RGR, RIG, RIGP, RJET, RLJ, RNR, RST, SBAC, SBY, SCSS, SD, SF, SGM, SLF, SPPI, SQNM, STR, SUN, SWM, SXL, TCAP, TEP, TROX, TS, TSE, TUMI, TWO, TXMD, UHAL, VEC, VVUS, WFM, WMGI, WPX, WRK, WSR, WTI, XENT, XNPT, XPO
Oct. 13, 2015, 12:36 PM
- MDxHealth SA (OTC:MXDHF) launches a urine-based test, called SelectMDx, for prostate cancer in Europe. The test will be offered as a service through its laboratory facilities in Nijmegen, the Netherlands.
- Initially, testing will be restricted to the Netherlands but will expand to other European countries in early 2016. It expects to be the principal provider of urine-based prostate cancer testing for patients with elevated (3 - 10 ng/ml) PSA levels in the Netherlands.
- The value proposition of the test, called a "liquid biopsy," is reliable identification of patients at low risk of prostate cancer while avoiding an invasive and typically painful tissue biopsy, which fails to find cancer 2/3 of the time.
- Related tickers: (TROV -2.8%)(BIOC +0.8%)(TBIO +5.5%)(SQNM -4.5%)
Oct. 12, 2015, 10:12 AM
- Sequenom (SQNM -2.8%) inks a clinical collaboration agreement with University Medical Center Hamburg-Eppendorf in Germany with the aim of profiling circulating cell-free DNA in blood to monitor response to treatment in patients with later stage colorectal cancer. It is its first oncology collaboration with a leading cancer center in Europe.
- The company is developing a Research Use Only (RUO) assay that will detect and profile late-stage non-hematologic malignancies in settings where tissue biopsies are not possible or too risky to obtain. The test will cover a range of cancer types by analyzing over 100 cancer-related genes.
Oct. 2, 2015, 12:40 PM
Sep. 25, 2015, 12:47 PM
Sep. 17, 2015, 9:15 AM
Sep. 17, 2015, 8:55 AM
- Sequenom Laboratories (NASDAQ:SQNM) signs a national contract with UnitedHealth Insurance to provide coverage of the company's MaterniT21 PLUS, HerediT CF Carrier Screen and HerediT UNIVERSAL Carrier Screen laboratory-developed tests. The agreement, effective October 1, covers 43M Americans.
- The MaterniT21 PLUS test detects fetal chromosomal abnormalities as early as 10 weeks into a pregnancy. The HerediT CF Carrier Screening test detects the most clinically relevant chromosomal abnormalities related to cystic fibrosis. The tests are performed in the company's laboratories as a service.
- Shares are up 9% premarket on light volume.
Aug. 26, 2015, 9:14 AM
Aug. 5, 2015, 5:38 PM
Sequenom, Inc. provides early patient management information. It develops and commercializes molecular diagnostic testing services that serve women's health and oncology markets. The company was founded by Hubert Koester and Charles R. Cantor in 1994 and is headquartered in San Diego, CA.
Country: United States
Other News & PR